#ZEO ScientifiX Enhances Leadership in Regenerative Medicine
On June 9, 2026, ZEO ScientifiX, Inc. (OTCQB:ZEOX) announced a significant expansion of its Medical Advisory Board, adding nine distinguished professionals in regenerative and longevity medicine. This initiative aims to strengthen the company's scientific credibility and support physician education in a field that is rapidly evolving.
The newly appointed members consist of leaders from various specialized areas, including:
Andrea Asseff-Llanes, DDS - Specialist in regenerative dental medicine.
Elizabeth Parrish - Founder and CEO of BioViva Sciences, a pioneer in gene-based longevity technology.
Faryal Farooqi, MD - Focused on longevity medicine and metabolic health.
Michael Swartzon, MD - An orthopedic sports medicine physician.
Mark A. Rosenberg, MD - President of Advanced Medical Therapeutics.
Constantino Mendieta, MD - Recognized for regenerative surgical techniques.
Neel Amin, MD - An expert in interventional pain medicine.
David Karli, MD - A researcher in orthopedic regenerative medicine.
Jacob Sanchez, CRNA, APRN - Specializes in aesthetic medicine.
#Commitment to Scientific Integrity and Physician Education
ZEO ScientifiX emphasizes a science-first approach, focusing on clinical research and educational initiatives rather than marketing alone. The existing advisory board, led by Chief Medical Officer Dr. George C. Shapiro, is tasked with maintaining high clinical standards in biological therapies and educational offerings.
As the regulatory landscape for regenerative medicine continues to evolve, particularly in states such as Georgia, Tennessee, and Florida, the board will guide the company’s strategic efforts to enhance clinical protocols and educational programming.
The expansion of the Medical Advisory Board will play a pivotal role in advancing clinical innovation and setting standards in the regenerative medicine sector. With seasoned experts onboard, ZEO ScientifiX aims to navigate the dynamic opportunities and challenges presented by this field.
The expansion indicates ZEO ScientifiX's commitment to enhancing its scientific foundation and clinical capabilities within the rapidly evolving field of regenerative medicine. A more robust advisory board suggests stronger expertise and guidance, positioning the company well to lead in innovative healthcare solutions.
As regulatory environments evolve and access to regenerative therapies increases in states like Florida, Georgia, and Tennessee, ZEO ScientifiX stands to benefit from heightened market opportunities. This trend may enhance the company’s ability to expand its services and reach within the healthcare continuum.
The Medical Advisory Board serves as a core scientific entity, ensuring that ZEO ScientifiX’s educational programmes and biologic offerings are grounded in rigorous clinical standards. This focus on research and education can foster greater trust and credibility with healthcare providers.
The inclusion of distinguished professionals such as Dr. Elizabeth Parrish and Dr. Mark A. Rosenberg underscores ZEO ScientifiX’s commitment to tapping into top-tier knowledge in regenerative and longevity medicine. These experts can significantly enhance the company’s innovation and clinical strategy.
ZEO ScientifiX emphasises a science-first approach, prioritising research and clinical integrity before marketing its products. This philosophy could differentiate the company from competitors who may focus more heavily on marketing than on foundational research.
Engagement in prestigious initiatives such as the XPRIZE competition positions ZEO ScientifiX among leading innovators in healthcare. Success in such competitions can elevate the company's visibility, attract investment, and stimulate partnerships, ultimately driving long-term growth.
By offering comprehensive educational programmes for physicians, ZEO ScientifiX can cultivate a well-informed network of practitioners. This not only supports the adoption of its products but also helps establish the company as a trusted leader in advancing regenerative medicine practices.
With an expanding advisory board, enhanced research capabilities, and a focus on high-quality standards in regenerative therapies, ZEO ScientifiX appears well-positioned to leverage emerging opportunities in the healthcare market, suggesting a positive outlook for its growth in the coming years.